Across TCGA pan-cancer cohorts, EVPLL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EVPLL data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher EVPLL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EVPLL expression acts as an unfavorable survival marker.
STAD, ESCA, and TGCT are the cancer types where EVPLL Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.